Denali Therapeutics
Denali Therapeutics is seeking a Postdoctoral Scientist to join the Parkinson's and Rare Disease team, focusing on the basic cellular mechanisms of lysosomal dysfunction in Parkinson's disease. This role involves collaborating with a multi-institutional network to investigate how lysosomal risk variants impact cellular function and alpha-synuclein clearance. The position is part of a larger research effort funded by ASAP, working closely with academic collaborators to advance therapeutic development for neurodegenerative diseases.
Headquarters
South San Francisco, California, United States
Company Size
201-500 employees
Founded
2015
Denali Therapeutics brings the power of biotherapeutics to the whole body, including the brain. We discover, develop and deliver medicines for people living with serious diseases.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Denali Therapeutics.